In France, over 1.5 million people suffer from mild cognitive impairment, often a precursor to Alzheimer's disease (AD), whose global prevalence could reach 153 million by 2050. With no curative treatment available, maintaining patients' autonomy at home is essential to mitigate the negative effects of institutionalization and reduce economic costs. Non-pharmacological approaches, such as cognitiv…
In France, over 1.5 million people suffer from mild cognitive impairment, often a precursor to Alzheimer's disease (AD), whose global prevalence could reach 153 million by 2050. With no curative treatment available, maintaining patients' autonomy at home is essential to mitigate the negative effects of institutionalization and reduce economic costs. Non-pharmacological approaches, such as cognitive training, have shown potential in stabilizing cognitive functions. Research suggests that motor networks and procedural memory remain relatively preserved in early AD, and bodily engagement during encoding enhances memory. For patients with motor impairments, motor imagery (MI) activates these networks without actual movement. Additionally, dynamic visual cues, like videos, reduce cognitive load compared to static images. This project aims to combine real action, MI, and dynamic visual supports to optimize memory. By validating 120 videos of daily activities, it will assess the impact of action on recall, evaluate MI's effectiveness for patients with mobility limitations, and confirm the superiority of videos over static images. The results could support the development of digital tools, such as serious games, to enhance patients' autonomy and address aging-related challenges.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
Patient group: Diagnosis of Alzheimer's disease made by one of the consulting physicians-a neurologist and/or geriatrician (Dubois et al., 2014)-at the early stage, presenting with mild memory impairment of which the patient has been informed
\- MMSE score of 21 or higher
Cont…
Inclusion Criteria:
Patient group: Diagnosis of Alzheimer's disease made by one of the consulting physicians-a neurologist and/or geriatrician (Dubois et al., 2014)-at the early stage, presenting with mild memory impairment of which the patient has been informed
\- MMSE score of 21 or higher
Control group: individuals without a diagnosis of Alzheimer's disease, but meeting the other criteria listed below
* Enrollment in a social security program
* Age 60 or older
* French as a native language
* Consent to participate
Exclusion Criteria:
* Uncorrected visual or hearing impairments
* Language or motor impairments
* Delirium or psychosis.
* Medical treatment affecting vision, language, or motor skills (or participation in a study involving a drug or device that influences cognition).
* Refusal to participate.
* Inability to communicate
* Persons deprived of liberty by a judicial or administrative decision and adults subject to a legal protection measure or unable to express their consent
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.